The Anticancer Potential of Peroxisome Proliferator-Activated Receptor Antagonists-Reference-Cited by-同舟云学术

The Anticancer Potential of Peroxisome Proliferator-Activated Receptor Antagonists

Published:2018-01-10 Issue:3 Volume:13 Page:209-219
ISSN:1860-7179
Container-title:ChemMedChem
language:en
Short-container-title:ChemMedChem

Author:

De Lellis Laura¹²,Cimini Annamaria³⁴⁵,Veschi Serena¹²,Benedetti Elisabetta³,Amoroso Rosa¹^ORCID,Cama Alessandro¹²,Ammazzalorso Alessandra¹

Affiliation:

1. Department of Pharmacy; University of Chieti; Via dei Vestini 31 66100 Chieti Italy

2. Unit of General Pathology, CeSI-MeT; University of Chieti; Chieti Italy

3. Department of Life, Health and Environmental Sciences; University of L'Aquila; L'Aquila Italy

4. National Institute for Nuclear Physics (INFN); Gran Sasso National Laboratory (LNGS); Assergi (Aq) Italy

5. Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology; Temple University; 1900 N. 12th Street Philadelphia PA 19122 USA

Publisher

Wiley

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics,Molecular Medicine,Drug Discovery,Biochemistry,Pharmacology

Reference113 articles.

1. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

2. Peroxisome proliferator-activated receptor structures: Ligand specificity, molecular switch and interactions with regulators

3. From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions

4. PPARs: therapeutic targets for metabolic disease

5. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors and

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding lactate in the development of Hepatitis B virus-related hepatocellular carcinoma;Infectious Agents and Cancer;2024-07-15

2. Peroxisome Proliferator-Activated Receptor agonists and antagonists: an updated patent review (2020–2023);Expert Opinion on Therapeutic Patents;2024-02

3. Roles of PPAR activation in cancer therapeutic resistance: Implications for combination therapy and drug development;European Journal of Pharmacology;2024-02

4. Phenylsulfonimide PPARα Antagonists Enhance Nrf2 Activation and Promote Oxidative Stress-Induced Apoptosis/Pyroptosis in MCF7 Breast Cancer Cells;International Journal of Molecular Sciences;2023-01-10

5. The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics;Experimental and Molecular Pathology;2022-02